Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT05273814
Phase
PHASE1
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tislelizumab — DRUG
    Tislelizumab intravenous infusion 200mg d4
  • Pemetrexed — DRUG
    Pemetrexed intravenous infusion 500mg/m2 d1
  • Bevacizumab — DRUG
    Pemetrexed intravenous infusion 7.5mg/kg，d1

Study Details

This single-center, open-label, phaseⅠstudy is to evaluate the efficacy of Tislelizumab in combination with Bevacizumab and Pemetrexed for the first-line treatment of advanced Non-squamous Non-small Cell lung cancer in Elderly Patients

Key Dates

First listed
Mar 10, 2022
Start date
Aug 1, 2022
Status verified
Jan 2022
Primary completion
Aug 1, 2023
Completion
Feb 1, 2024

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tislelizumab+Bevacizumab+Pemetrexed
    Bevacizumab，7.5mg/kg，d1; Pemetrexed，500mg/m2，d1; Tislelizumab，200mg，d4; Q3W for 4 cycles; Maintenance treatment ： Tislelizumab，200mg，d1; Bevacizumab，7.5mg/kg，d1; Q3W for 2 years

Primary Outcome Measure

Objective response rate [ Time Frame: approximately 2 years ]

Related Studies